公开(公告)号：US08017592B2

公开(公告)日：2011-09-13

申请号：US12296565

申请日：2007-04-10

申请人： John M. Yanni ,  Jon E. Chatterton ,  Daniel A. Gamache ,  Steven T. Miller

发明人： John M. Yanni ,  Jon E. Chatterton ,  Daniel A. Gamache ,  Steven T. Miller

IPC分类号： A01N43/04 ,  A61K31/70

CPC分类号： C12N15/1138 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/141

摘要： RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

摘要翻译： 提供RNA干扰用于抑制组胺受体H1mRNA表达，特别是用于治疗患有HRH1相关病症或具有发生HRH1相关病症的风险的患者，例如过敏性结膜炎，眼部炎症，皮炎，鼻炎，哮喘或 过敏。

公开(公告)号：US20110142767A1

公开(公告)日：2011-06-16

申请号：US13035147

申请日：2011-02-25

申请人： John M. Yanni ,  Jon E. Chatterton ,  Diane Michelle Senchyna ,  Daniel A. Gamache ,  Steven T. Miller

发明人： John M. Yanni ,  Jon E. Chatterton ,  Diane Michelle Senchyna ,  Daniel A. Gamache ,  Steven T. Miller

IPC分类号： A61K9/12 ,  A61K31/7088

CPC分类号： C12N15/1138 ,  A61K31/7088 ,  A61K31/713 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2320/30

摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这样的TNFα靶标可用于治疗患有TNFα相关病症或具有发展TNFα相关病症如眼病干眼症，过敏性结膜炎或眼部炎症或诸如皮炎，鼻炎的患者的患者 ，或哮喘。

公开(公告)号：US20090274631A1

公开(公告)日：2009-11-05

申请号：US12296565

申请日：2007-04-10

申请人： John M. Yanni ,  Jon E. Chatterton ,  Daniel A. Gamache ,  Steven T. Miller

发明人： John M. Yanni ,  Jon E. Chatterton ,  Daniel A. Gamache ,  Steven T. Miller

IPC分类号： A61K9/12 ,  A61K31/7088

CPC分类号： C12N15/1138 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/141

摘要： RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

摘要翻译： 提供RNA干扰用于抑制组胺受体H1mRNA表达，特别是用于治疗患有HRH1相关病症或具有发生HRH1相关病症的风险的患者，例如过敏性结膜炎，眼部炎症，皮炎，鼻炎，哮喘或 过敏。

公开(公告)号：US20080139531A1

公开(公告)日：2008-06-12

申请号：US11947041

申请日：2007-11-29

申请人： John M. Yanni ,  Daniel A. Gamache ,  Steven T. Miller

发明人： John M. Yanni ,  Daniel A. Gamache ,  Steven T. Miller

IPC分类号： A61K31/55 ,  A61K31/335 ,  A61K31/519 ,  A61K31/505 ,  A61K31/4422

CPC分类号： A61K31/335 ,  A61K31/4422 ,  A61K31/505 ,  A61K31/519 ,  A61K31/55

摘要： Disclosed are methods of treating a wound in a subject that involve administering to the subject a pharmaceutically effective amount of a composition that includes one or more human connective tissue mast cell stabilizers, wherein administration of the composition results in treatment of the wound. In particular embodiments, the wound is an ophthalmic or dermal wound, such as a corneal epithelial defect, a conjunctival wound, or dermal abrasion. Administration, for example, may be by topical application of the composition to the ocular surface or skin. Exemplary mast cell stabilizers include olopatadine, variants of olopatadine, alcaftidine, derivatives of alcaftidine, dihydropyridines, and spleen tyrosine kinase inhibitors.

摘要翻译： 公开了治疗受试者中伤口的方法，其涉及向受试者施用药学有效量的包含一种或多种人结缔组织肥大细胞稳定剂的组合物，其中施用组合物导致伤口的治疗。 在具体实施方案中，伤口是眼部或皮肤伤口，例如角膜上皮缺损，结膜伤口或皮肤磨损。 例如，施用可以通过将组合物局部施用于眼表面或皮肤。 示例性肥大细胞稳定剂包括奥洛他定，奥洛他定，阿司匹啶，阿司匹啶衍生物，二氢吡啶类和脾脏酪氨酸激酶抑制剂的变体。